India Healthcare Pharma Policy Regulatory Filings — May 16, 2026

Revenue grew 12% YoY (vs sector avg 7%), driven by 22% rise in government scheme admissions

EBITDA margin expanded 80 bps QoQ to 19.4%, outperforming peers by 120 bps

Management maintained FY27 capacity guidance of +15% beds with no cuts

Dividend held steady at ₹18/share for 4th consecutive year, payout ratio stable at 22%

Debt-to-Equity improved to 0.38 from 0.45 YoY, reflecting prudent capital allocation

Occupancy rate rose 340 bps YoY to 68%, above industry average of 61%

Forward-looking target of 25% revenue contribution from Tier-2/3 cities by 2028 reiterated

No insider selling recorded in the period, with promoter holding steady at 29.8%

Average revenue per bed under Ayushman Bharat declined 4% YoY due to tariff revisions

SEBI compliance costs expected to rise 8-10% in FY27 from new disclosure rules

Medical consumable costs up 6% QoQ, partially offsetting margin gains

FY27 capex guidance of ₹1,200 Cr unchanged but funding mix tilted 15% toward debt

Peer hospital chains reporting faster 18% YoY volume growth in same schemes

Expected inclusion in expanded Ayushman Bharat Phase-II rollout from Q4 2026 could add 8-10% volume

Trading at 28x FY27E EPS vs sector 34x, with superior ROE of 14.2%

Zero promoter pledge as of May 2026 signals strong conviction ahead of policy catalysts

Potential special dividend or buyback possible if FCF exceeds ₹800 Cr target

Ongoing evaluation of 2 distressed hospital assets in South India at attractive valuations

Digital health vertical expected to contribute 5% revenue by FY28 at 35%+ margins

Government scheme admissions across healthcare rose 15% YoY for Apollo, consistent with sector trend of 12-18% growth in policy-driven volumes

Apollo achieved 80 bps margin expansion even as reimbursement rates softened, outperforming peers facing 100-150 bps compression

No buybacks or aggressive leverage observed; focus remains on organic bed addition, aligning with conservative sector stance post-rate cut cycle

Apollo's low-risk profile on new SEBI norms positions it favorably versus mid-sized hospitals likely to face higher compliance costs

Q1 FY27 earnings call on Aug 12 2026 - monitor Ayushman Bharat volume commentary and FY27 guidance updates

SEBI healthcare disclosure compliance filing due Sep 30 2026 - watch for any cost or operational impact disclosures

Promoter shareholding change watch through Nov 2026; any increase could signal further conviction

Potential M&A announcement on distressed assets expected by Q3 FY27 - track deal terms and accretion guidance